Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive

ISSN： 0114-5916

Source： Drug Safety, Vol.32, Iss.3, 2009-01, pp. : 187-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone takes a proactive stance in type 2 diabetes

Inpharma, Vol. 1, Iss. 1507, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Postmarketing Surveillance Study of the Efficacy and Tolerability of Pioglitazone in Insulin-Resistant Patients with Type 2 Diabetes Mellitus in General Practice

By Schöfl C.

Clinical Drug Investigation, Vol. 23, Iss. 11, 2003-01 ,pp. : 725-734

Adis International

Access to resources Recommend Favorite

Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus: Comparison with Other Oral Antihyperglycaemic Agents

By Derosa Giuseppe

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1945-1961

Adis International

Access to resources Recommend Favorite

Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone: Results from a 3-Year, Randomized, Comparator-Controlled Study in the US

By Tolman Keith G.

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 787-800

Adis International

Access to resources Recommend Favorite

Preventing Type 2 Diabetes in High Risk Patients: An Overview of Lifestyle and Pharmacological Measures

Current Drug Targets, Vol. 7, Iss. 2, 2006-01 ,pp. : 211-228

Bentham Science Publishers

Access to resources Recommend Favorite